BioCentury | Feb 15, 2016
Clinical News

Peptide vaccine: Phase Ib started

...levels of subcutaneous CV-MG01 on days 1, 29 and 85 in about 32 adult patients. CuraVac Inc....
BioCentury | Oct 29, 2012
Emerging Company Profile

Regenesance: Stopping the MAC attack

...stop complement activation. Baas said he was not familiar with a pre-clinical peptide vaccine from CuraVac Inc....
...ALS Therapy Development Institute (ALS TDI), Cambridge, Mass. Bayhill Therapeutics Inc. , San Mateo, Calif. CuraVac Inc....
BioCentury | Sep 21, 2009
Clinical News

Peptide vaccine regulatory update

...for Orphan Medicinal Products (COMP) issued a positive opinion to grant Orphan Drug designation for CuraVac's...
...that mimic antigen receptors on autoimmune B cells and T cells associated with myasthenia gravis. CuraVac Inc....
Items per page:
1 - 3 of 3
BioCentury | Feb 15, 2016
Clinical News

Peptide vaccine: Phase Ib started

...levels of subcutaneous CV-MG01 on days 1, 29 and 85 in about 32 adult patients. CuraVac Inc....
BioCentury | Oct 29, 2012
Emerging Company Profile

Regenesance: Stopping the MAC attack

...stop complement activation. Baas said he was not familiar with a pre-clinical peptide vaccine from CuraVac Inc....
...ALS Therapy Development Institute (ALS TDI), Cambridge, Mass. Bayhill Therapeutics Inc. , San Mateo, Calif. CuraVac Inc....
BioCentury | Sep 21, 2009
Clinical News

Peptide vaccine regulatory update

...for Orphan Medicinal Products (COMP) issued a positive opinion to grant Orphan Drug designation for CuraVac's...
...that mimic antigen receptors on autoimmune B cells and T cells associated with myasthenia gravis. CuraVac Inc....
Items per page:
1 - 3 of 3